• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Unanswered questions regarding the management of sunitinib-induced hypothyroidism.

作者信息

Garfield David, Hercbergs Aleck, Davis Paul

机构信息

Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80209, USA.

出版信息

Nat Clin Pract Oncol. 2007 Dec;4(12):674. doi: 10.1038/ncponc0998. Epub 2007 Oct 23.

DOI:10.1038/ncponc0998
PMID:17955044
Abstract
摘要

相似文献

1
Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
Nat Clin Pract Oncol. 2007 Dec;4(12):674. doi: 10.1038/ncponc0998. Epub 2007 Oct 23.
2
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.回复：舒尼替尼治疗转移性肾细胞癌患者中的甲状腺功能减退症
J Natl Cancer Inst. 2007 Jun 20;99(12):975-6; author reply 976-7. doi: 10.1093/jnci/djm008. Epub 2007 Jun 12.
3
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.回复：舒尼替尼治疗转移性肾细胞癌患者的甲状腺功能减退症
J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. doi: 10.1093/jnci/djm006. Epub 2007 Jun 12.
4
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.舒尼替尼治疗的转移性肾细胞癌患者中的甲状腺功能减退症
J Natl Cancer Inst. 2007 Jan 3;99(1):81-3. doi: 10.1093/jnci/djk008.
5
Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.患者摘要。舒尼替尼治疗胃肠道癌后甲状腺功能减退。
Ann Intern Med. 2006 Nov 7;145(9):I44. doi: 10.7326/0003-4819-145-9-200611070-00004.
6
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.舒尼替尼治疗胃肠道间质瘤患者后出现的甲状腺功能减退
Ann Intern Med. 2006 Nov 7;145(9):660-4. doi: 10.7326/0003-4819-145-9-200611070-00008.
7
How does sunitinib cause hypothyroidism?
Thyroid. 2010 Mar;20(3):243-4. doi: 10.1089/thy.2010.1620.
8
Acute severe hypothyroidism induced by sunitinib.
Radiother Oncol. 2008 Oct;89(1):124-5. doi: 10.1016/j.radonc.2008.05.007. Epub 2008 May 24.
9
Documentation of thyroid function in clinical studies with sunitinib: why does it matter?
J Clin Oncol. 2008 Nov 1;26(31):5131-2; author reply 5132-3. doi: 10.1200/JCO.2008.18.8680. Epub 2008 Sep 29.
10
Sunitinib adverse event: oral bullous and lichenoid mucositis.舒尼替尼不良事件：口腔大疱性和苔藓样粘膜炎。
Ann Pharmacother. 2009 Mar;43(3):546-7. doi: 10.1345/aph.1L592. Epub 2009 Feb 24.

引用本文的文献

1
Impact of Tyrosine Kinase Inhibitors on Thyroid Function in Chronic Myeloid Leukemia: A Systematic Review.酪氨酸激酶抑制剂对慢性髓性白血病甲状腺功能的影响：一项系统评价
Cureus. 2025 Jun 1;17(6):e85196. doi: 10.7759/cureus.85196. eCollection 2025 Jun.
2
Detection of strain types and analysis of risk factors among subjects from Hainan Province, China.中国海南省人群中 株型的检测及危险因素分析。
J Int Med Res. 2024 May;52(5):3000605241253454. doi: 10.1177/03000605241253454.
3
Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
中国胃肠间质瘤酪氨酸激酶抑制剂相关不良反应管理专家共识。
World J Gastroenterol. 2018 Dec 14;24(46):5189-5202. doi: 10.3748/wjg.v24.i46.5189.
4
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.激酶抑制剂和单克隆抗体在肿瘤学中的临床应用。
Nat Rev Clin Oncol. 2016 Apr;13(4):209-27. doi: 10.1038/nrclinonc.2015.213. Epub 2015 Dec 31.
5
Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.酪氨酸激酶抑制剂引起的甲状腺功能障碍：发病率、病理生理学、临床相关性和治疗的综述。
Biomed Res Int. 2013;2013:725410. doi: 10.1155/2013/725410. Epub 2013 Oct 27.
6
Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.酪氨酸激酶抑制剂引起的甲状腺功能减退症：发病率、病因和治疗。
Target Oncol. 2011 Dec;6(4):217-26. doi: 10.1007/s11523-011-0197-2. Epub 2011 Nov 19.
7
Thyroid dysfunction from antineoplastic agents.抗肿瘤药物引起的甲状腺功能障碍。
J Natl Cancer Inst. 2011 Nov 2;103(21):1572-87. doi: 10.1093/jnci/djr373. Epub 2011 Oct 18.
8
Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.酪氨酸激酶抑制剂II期研究中临床相关安全数据持续报告不足。
Br J Cancer. 2010 Apr 13;102(8):1309-10; author reply 1311. doi: 10.1038/sj.bjc.6605628. Epub 2010 Mar 30.
9
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.与酪氨酸激酶抑制剂相关的甲状腺功能减退：靶向治疗的一种新出现的毒性作用。
Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4.